Nearly a decade after FDA clearance the HyProCure stent has helped thousands to safely and effectively eliminate recurrent foot pain and secondary symptoms associated with the partial dislocation of the ankle bone on the heel bone.
Macomb Township, MI (PRWEB) April 23, 2013
http://www.hyprocure.com In a recent study published in the Journal of Foot & Ankle Surgery, the HyProCure implant -- a small, titanium stent developed to address a partial dislocation of the ankle bone on the heel bone -- results in substantial improvement in foot pain and foot function.
Additionally, patients diagnosed with said secondary conditions such as plantar fasciitis, bunions and hammertoes, had been relieved of these symptoms without additional surgery.
Participating surgeons had all received previously procedural training through the Graham International Implant Institute and all had a minimum experience of two years with this device and procedure.
The prospective study measured the changes in subjective outcomes in patients, scoring three separate and distinct areas: 1) Foot Pain, 2) Foot Function and 3) Appearance. Scores were defined pre-operatively and at clearly defined intervals post-operatively as follows:
- Once each week for a period of three weeks (or three times in three consecutive weeks)
- Once every one, three and six months
- Reexamination & evaluation after the period of one year (post operatively)
The prospective study identifies improvement in overall scores from a preoperative value of 69.53 (± 19.56) to a postoperative value of 89.17 (± 14.41) after a period of 1-year in the follow-up examination.
- Foot Pain was reduced by 36.97%
- Foot Functional & Activity improved by 14.39%
- Foot Appearance improved by 29.49%
- The greatest magnitude of improvement occurred four (4) weeks post-operatively, with gradual improvement continuing right up to the 1-year follow up examination
- Implants were only removed from 2 patients (2 feet – or 4.35%)
- The removal rate was down from 5.94% or 4.35%
- The 5.94% removal rate reduction was retrospectively on 117 feet (while this study was on 46 feet) at a mean follow-up of 51 months
“We’re extremely pleased with the Prospective Study results. The data and success rates are very consistent with our internal results and procedural benchmark projections, so we’re not entirely surprised,” notes Dr. Michael E. Graham, and HyProCure innovator and pioneer. “Other types of implants often yield varied and less than perfect patient outcomes. We didn’t want a temporary fix, and the team has worked diligently to mitigate any removal rates…the success of the procedure is only to the advantage of both the surgeon and the patient,” Graham adds. “We’re anxiously awaiting the [positive] news from the next study.”
Nearly a decade after FDA clearance and the formal adoption of a procedural norm, the HyProCure stent has helped thousands to safely and effectively eliminate recurrent foot pain and secondary symptoms associated with the partial dislocation of the ankle bone on the heel bone. The Graham Institute continues to engage in ongoing research & development as well as the refinement of physician training in support of the one mission and end goal – Feet are the Foundation. HyProCure continues to support surgeons worldwide with comprehensive training and certification programs in support of the correct procedural methodology associated with the HyProCure stent.
HyProCure is an internal stabilization device that is placed inside the foot to correct recurrent or partial talotarsal dislocation (RTTD), a common condition that can produce painful symptoms, side effects and associated secondary conditions throughout the body. The displacement of the ankle bone (talus) collapses the sinus tarsi, leading to abnormal weight-distribution resulting in both misalignment and recurrent pain. The HyProCure stent maintains the natural opening of the sinus tarsi, realigning the ankle bone while instantly stabilizing and restoring the foot's normal anatomy - while correcting the mechanics that resulting in imbalance throughout the rest of the body. HyProCure is a minimally invasive corrective solution for RTTD and excessive foot pronation, and the procedure is typically performed under twilight-anesthesia in an outpatient environment.
GraMedica was founded in 2003 and the Graham International Implant Institute was founded in 2004. Both are uniquely committed to the worldwide understanding and treatment of RTTD and the HyProCure procedure as a means to that end as well as other related foot abnormalities. HyProCure is available across the United States and internationally.
# # # #
To learn more about HyProCure or foot, ankle, knee, hip and back pain that may be associated with RTTD, visit http://www.hyprocure.com.
Foot surgeons are invited to learn more about the HyProCure procedure at http://www.hyprocuredoctors.com, or find a live surgical training seminar in your area or region.
Press queries should be directed to Tara Hasouris at mo marketing + pr via email: tara(at)lessismo(dot)com